This German Biotech Just Raised Millions to Tackle a Silent Heart Disease Epidemic

Jan de Vries · 2026-08-28

Let's talk about something that's quietly reshaping the European biotech scene. A new player has just entered the arena with a mission that could change lives. Revier Therapeutics, based out of Heidelberg, Germany, has officially launched and secured a $6.5 million Seed round. That's right, they've turned that €6 million into a serious war chest to take on some of the most challenging cardiometabolic diseases out there. It's not just another funding announcement. This feels different. The round was led by the KHAN Technology Transfer Fund II, with High-Tech Gründerfonds (HTGF), VORNvc, and private investors from Revier Invest Heidelberg also jumping in. They're backing a specific, science-driven vision. ### The Problem They're Solving Here's the thing—despite all our medical advances, millions of patients are still stuck. Prof. Eva van Rooij, the company's CEO, puts it plainly. Patients with HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease) often hit a wall. Treatment options are limited. The current approach often manages symptoms rather than tackling the root cause. Revier believes the next generation of medicine needs to go deeper, addressing the underlying biology that drives these diseases. It's about creating lasting solutions, not just temporary fixes. Their mission? To translate the complex science of class IIa HDAC inhibition into real, tangible therapies. And they want to move fast from the lab to the clinic. ### A New Kind of Therapeutic Approach So, what makes them stand out? Revier is pioneering the first therapeutic approach to *selectively* target class IIa histone deacetylases (HDACs) for cardiometabolic diseases. In simpler terms, HDACs are enzymes involved in many serious diseases. Past attempts to inhibit them were like using a sledgehammer—they hit everything, causing significant side effects. Revier's strategy is more like a precision scalpel. Their orally available small molecules are designed to do two key things: - Inhibit the specific, disease-causing enzymatic activity. - Preserve the healthy, essential biological functions of these enzymes. Prof. Johannes Backs, the scientific founder, explains the breakthrough. Earlier HDAC inhibitors broadly targeted multiple classes, leading to those dose-limiting problems. Revier's compounds are first-in-class. They selectively go after class IIa HDACs, aiming to stop the disease process without wrecking the body's normal functions. ### Why Investors Are Betting on This Team The confidence from investors isn't just about the science—it's about the people executing it. Michael Hamacher from KHAN Technology Transfer Fund II highlighted the combination of a differentiated strategy and an exceptional leadership team. He sees the potential to not just create another drug, but to reshape the standard of care for HFpEF, ASCVD, and related disorders. The goal is durable patient benefit. ### What's Next for the Capital? With $6.5 million in the bank, the plan is clear. The money will fuel: - The preclinical development of their cardiometabolic pipeline. - Advancing their lead program in HFpEF. - Progressing their second program in ASCVD. - Building out their operational, scientific, and clinical teams. It's a classic seed-stage play: prove the concept, build the foundation, and prepare for the next phase. For professionals watching the European startup ecosystem, especially in life sciences, Revier Therapeutics is a name to remember. They represent a shift towards highly targeted, biology-first therapies emerging from deep academic roots. Their success could signal a new wave of innovation tackling chronic diseases that have long needed better answers.